CS08399
MTAP-Deficient Tumors
IND ApprovedClinical development imminent
Key Facts
Indication
MTAP-Deficient Tumors
Phase
IND Approved
Status
Clinical development imminent
Company
About Chipscreen Biosciences
A Chinese biotech pioneer developing original small molecule drugs for oncology and metabolic diseases using chemical genomics and AI platforms.
View full company profile